Literature DB >> 27699124

Chemotherapeutic drug-specific alteration of microvascular blood flow in murine breast cancer as measured by diffuse correlation spectroscopy.

Gabriel Ramirez1, Ashley R Proctor1, Ki Won Jung1, Tong Tong Wu2, Songfeng Han3, Russell R Adams1, Jingxuan Ren1, Daniel K Byun1, Kelley S Madden1, Edward B Brown1, Thomas H Foster4, Parisa Farzam5, Turgut Durduran6, Regine Choe7.   

Abstract

The non-invasive, in vivo measurement of microvascular blood flow has the potential to enhance breast cancer therapy monitoring. Here, longitudinal blood flow of 4T1 murine breast cancer (N=125) under chemotherapy was quantified with diffuse correlation spectroscopy based on layer models. Six different treatment regimens involving doxorubicin, cyclophosphamide, and paclitaxel at clinically relevant doses were investigated. Treatments with cyclophosphamide increased blood flow as early as 3 days after administration, whereas paclitaxel induced a transient blood flow decrease at 1 day after administration. Early blood flow changes correlated strongly with the treatment outcome and distinguished treated from untreated mice individually for effective treatments.

Entities:  

Keywords:  (170.3660) Light propagation in tissues; (170.6480) Spectroscopy, speckle; (290.4210) Multiple scattering

Year:  2016        PMID: 27699124      PMCID: PMC5030036          DOI: 10.1364/BOE.7.003610

Source DB:  PubMed          Journal:  Biomed Opt Express        ISSN: 2156-7085            Impact factor:   3.732


  68 in total

1.  In vivo determination of the optical properties of muscle with time-resolved reflectance using a layered model.

Authors:  A Kienle; T Glanzmann
Journal:  Phys Med Biol       Date:  1999-11       Impact factor: 3.609

Review 2.  Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance.

Authors:  P Vaupel; M Hockel
Journal:  Int J Oncol       Date:  2000-11       Impact factor: 5.650

Review 3.  Applications of magnetic resonance in model systems: cancer therapeutics.

Authors:  J L Evelhoch; R J Gillies; G S Karczmar; J A Koutcher; R J Maxwell; O Nalcioglu; N Raghunand; S M Ronen; B D Ross; H M Swartz
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

Review 4.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects.

Authors:  M Höckel; P Vaupel
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

5.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

Authors:  Marc L Citron; Donald A Berry; Constance Cirrincione; Clifford Hudis; Eric P Winer; William J Gradishar; Nancy E Davidson; Silvana Martino; Robert Livingston; James N Ingle; Edith A Perez; John Carpenter; David Hurd; James F Holland; Barbara L Smith; Carolyn I Sartor; Eleanor H Leung; Jeffrey Abrams; Richard L Schilsky; Hyman B Muss; Larry Norton
Journal:  J Clin Oncol       Date:  2003-02-13       Impact factor: 44.544

Review 6.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

7.  Commercial taxane formulations induce stomatocytosis and increase blood viscosity.

Authors:  M Mark; R Walter; D O Meredith; W H Reinhart
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

8.  Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway.

Authors:  Eddy Pasquier; Manon Carré; Bertrand Pourroy; Laurence Camoin; Ouafa Rebaï; Claudette Briand; Diane Braguer
Journal:  Mol Cancer Ther       Date:  2004-10       Impact factor: 6.261

Review 9.  Current status and future directions in breast cancer therapy.

Authors:  Clifford A Hudis
Journal:  Clin Breast Cancer       Date:  2003-11       Impact factor: 3.225

10.  Monitoring neoadjuvant chemotherapy in breast cancer using quantitative diffuse optical spectroscopy: a case study.

Authors:  Dorota B Jakubowski; Albert E Cerussi; Frédéric Bevilacqua; Natasha Shah; David Hsiang; John Butler; Bruce J Tromberg
Journal:  J Biomed Opt       Date:  2004 Jan-Feb       Impact factor: 3.170

View more
  5 in total

1.  Longitudinal optical monitoring of blood flow in breast tumors during neoadjuvant chemotherapy.

Authors:  J M Cochran; S H Chung; A Leproux; W B Baker; D R Busch; A M DeMichele; J Tchou; B J Tromberg; A G Yodh
Journal:  Phys Med Biol       Date:  2017-04-12       Impact factor: 3.609

2.  Small separation diffuse correlation spectroscopy for measurement of cerebral blood flow in rodents.

Authors:  Eashani Sathialingam; Seung Yup Lee; Bharat Sanders; Jaekeun Park; Courtney E McCracken; Leah Bryan; Erin M Buckley
Journal:  Biomed Opt Express       Date:  2018-10-25       Impact factor: 3.732

3.  Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics.

Authors:  Parisa Farzam; Johannes Johansson; Miguel Mireles; Gabriela Jiménez-Valerio; Mar Martínez-Lozano; Regine Choe; Oriol Casanovas; Turgut Durduran
Journal:  Biomed Opt Express       Date:  2017-04-19       Impact factor: 3.732

4.  Semiparametric mixed-effects model for analysis of non-invasive longitudinal hemodynamic responses during bone graft healing.

Authors:  Sami Leon; Jingxuan Ren; Regine Choe; Tong Tong Wu
Journal:  PLoS One       Date:  2022-04-05       Impact factor: 3.240

5.  Chemotherapeutic effects on breast tumor hemodynamics revealed by eigenspectra multispectral optoacoustic tomography (eMSOT).

Authors:  Evangelos Liapis; Angelos Karlas; Uwe Klemm; Vasilis Ntziachristos
Journal:  Theranostics       Date:  2021-06-26       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.